Tarsus Pharmaceuticals (TARS) Earnings Date, Estimates & Call Transcripts $41.70 +0.55 (+1.34%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$44.60 +2.90 (+6.95%) As of 08/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Tarsus Pharmaceuticals Earnings Summary Tarsus Pharmaceuticals announced Q2 2025 earnings on August 6, 2025, reporting an EPS of -$0.48, which missed analysts' consensus estimates of -$0.33 by $0.15. Quarterly revenue was reported to be $102.66 million, above the consensus estimate of $95.81 million. With a trailing EPS of -$2.73, Tarsus Pharmaceuticals' earnings are expected to grow next year, from ($3.17) to ($1.44) per share. Latest Q2 Earnings DateAug. 6EstimatedConsensus EPS (Aug. 6) -$0.33 Actual EPS (Aug. 6) -$0.48 Missed By -$0.15 Actual Revenue (Aug. 6) $102.66MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Tarsus Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tarsus Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTARS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TARS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Tarsus Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.82-$0.78-$0.80Q2 20253-$0.48-$0.41-$0.46Q3 20254-$0.35-$0.31-$0.33Q4 20253-$0.22-$0.05-$0.13 FY 2025 13 -$1.87 -$1.55 -$1.71 Q1 20261-$0.06-$0.06-$0.06Q2 20261$0.32$0.32$0.32Q3 20261$0.56$0.56$0.56Q4 20261$0.80$0.80$0.80 Tarsus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025-$0.33-$0.48 -$0.15-$0.48$95.81M$102.66M5/1/2025Q1 2025-$0.69-$0.64+$0.05-$0.64$72.50M$78.34M2/25/2025Q4 2024-$0.68-$0.60+$0.08-$0.60$58.80M$66.41M8/8/2024Q2 2024-$0.98-$0.88+$0.10-$0.88$31.30M$40.81M5/8/2024Q1 2024-$1.15-$1.01+$0.14-$1.01$17.94M$27.61M2/27/2024Q4 2023-$1.37-$1.31+$0.06-$1.31$4.63M$13.08M11/9/2023Q3 2023-$1.40-$1.28+$0.12-$1.28$0.72M$1.87M8/10/2023Q2 2023-$1.08-$1.17 -$0.09-$1.17-- Tarsus Pharmaceuticals Earnings - Frequently Asked Questions When did Tarsus Pharmaceuticals announce their last quarterly earnings? Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earning data on Wednesday, August 6, 2025. Learn more on TARS's earnings history. Did Tarsus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Tarsus Pharmaceuticals (NASDAQ:TARS) missed the analysts' consensus estimate of ($0.33) by $0.15 with a reported earnings per share (EPS) of ($0.48). Learn more on analysts' earnings estimate vs. TARS's actual earnings. How can I listen to Tarsus Pharmaceuticals' earnings conference call? The conference call for Tarsus Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Tarsus Pharmaceuticals' conference call transcript? The conference call transcript for Tarsus Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Tarsus Pharmaceuticals generate each year? Tarsus Pharmaceuticals (NASDAQ:TARS) has a recorded annual revenue of $182.95 million. How much profit does Tarsus Pharmaceuticals generate each year? Tarsus Pharmaceuticals (NASDAQ:TARS) has a recorded net income of -$115.55 million. TARS has generated -$2.73 earnings per share over the last four quarters. What is Tarsus Pharmaceuticals' EPS forecast for next year? Tarsus Pharmaceuticals' earnings are expected to grow from ($3.17) per share to ($1.44) per share in the next year. More Earnings Resources from MarketBeat Related Companies TG Therapeutics Earnings Date Nuvalent Earnings Date CRISPR Therapeutics Earnings Date Rhythm Pharmaceuticals Earnings Date Lantheus Earnings Date Axsome Therapeutics Earnings Date Vaxcyte Earnings Date Merus Earnings Date Cytokinetics Earnings Date Avidity Biosciences Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk ProductionAmazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT? This page (NASDAQ:TARS) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts